AtaiBeckley (ATAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Aug, 2026Voting and support agreement no
Representations and covenants do not survive termination.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AtaiBeckley
- Definitive merger with Eli Lilly announced; Q2 net loss $32.5M, cash $168.8M, key trials advancing.ATAI
Q2 2026 - Shareholders to vote on a $6.75 per share cash merger with Eli Lilly plus CVR up to $2.50.ATAIProxy filing
- Shareholders to vote on a merger offering up to $9.25 per share, closing expected Q3 2026.ATAIProxy filing
- Shareholders to vote on acquisition by Eli Lilly, advancing novel mental health therapies.ATAIProxy filing
- Shareholders will vote on a proposed acquisition by Eli Lilly, expected to close in Q3 2026.ATAIProxy filing
- Shareholders will vote on AtaiBeckley's acquisition by Eli Lilly, with clinical programs unaffected.ATAIProxy filing
- Shareholders will vote on a proposed acquisition by Eli Lilly, with closing expected in Q3 2026.ATAIProxy filing
- Definitive acquisition agreement with Eli Lilly targets Q3 2026 closing, pending approvals.ATAIProxy filing
- Shareholders will vote on a proposed acquisition by Eli Lilly, expected to close in Q3 2026.ATAIProxy filing